HDM201

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HDM201, covering 2025-10-10 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas [Phase 1, Phase 2]